Lack of complement inhibitors in the outer intracranial artery aneurysm wall associates with complement terminal pathway activation

American Journal of Pathology

Volumn 177, Issue 6, 2010, Pages 3224-3232

  Tulamo, Riikka ^a,b   Frösen, Juhana ^a,c   Paetau, Anders ^b   Seitsonen, Sanna ^b   Hernesniemi, Juha ^a,c   Niemelä, Mika ^a,c   Järvelä, Irma ^b   Meri, Seppo ^b  

^a BIOMEDICUM HELSINKI   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CD59 ANTIGEN; COMPLEMENT COMPONENT C4B BINDING PROTEIN; COMPLEMENT FACTOR H; COMPLEMENT MEMBRANE ATTACK COMPLEX; DECAY ACCELERATING FACTOR; GLYCOSAMINOGLYCAN; MEMBRANE COFACTOR PROTEIN;

ADULT; AGED; ANEURYSM RUPTURE; ARTERY WALL; ARTICLE; CLINICAL ARTICLE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOREGULATION; INFLAMMATION; INTRACRANIAL ANEURYSM; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 78650202961     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2010.091172     Document Type: Article

References (38)

1. Rinkel GJ, Djibuti M, Algra A, van Gijn J: Prevalence and risk of rupture of intracranial aneurysms: a systematic review. Stroke 1998, 29:251-256 (Pubitemid 28046972)
2. Ronkainen A, Miettinen H, Karkola K, Papinaho S, Vanninen R, Puranen M, Hernesniemi J: Risk of harboring an unruptured intracranial aneurysm. Stroke 1998, 29:359-362
3. Crompton MR: Mechanism of growth and rupture in cerebral berry aneurysms. Br Med J 1966, 1:1138-1142
4. Chyatte D, Bruno G, Desai S, Todor DR: Inflammation and intracranial aneurysms. Neurosurgery 1999, 45:1137-1146
5. Kataoka K, Taneda M, Asai T, Kinoshita A, Ito M, Kuroda R: Structural fragility and inflammatory response of ruptured cerebral aneurysms. A comparative study between ruptured and unruptured cerebral aneurysms. Stroke 1999, 30:1396-1401
6. Frösen J, Piippo A, Paetau A, Kangasniemi M, Niemelä M, Hernesniemi J, Jääskeläinen J: Remodeling of saccular cerebral artery aneurysm wall is associated with rupture: histological analysis of 24 unruptured and 42 ruptured cases. Stroke 2004, 35:2287-2293
7. Tulamo R, Frösen J, Junnikkala S, Paetau A, Pitkäniemi J, Kangasniemi M, Niemelä M, Jääskeläinen J, Jokitalo E, Karatas A, Hernesniemi J, Meri S: Complement activation associates with saccular cerebral artery aneurysm wall degeneration and rupture. Neurosurgery 2006, 59:1069-1076
8. Krischek B, Kasuya H, Tajima A, Akagawa H, Sasaki T, Yoneyama T, Ujiie H, Kubo O, Bonin M, Takakura K, Hori T, Inoue I: Network-based gene expression analysis of intracranial aneurysm tissue reveals role of antigen presenting cells. Neuroscience 2008, 154:1398-1407
9. Shi C, Awad IA, Jafari N, Lin S, Du P, Hage ZA, Shenkar R, Getch CC, Bredel M, Batjer HH, Bendok BR: Genomics of human intracranial aneurysm wall. Stroke 2009, 40:1252-1261
10. Tulamo R, Frösen J, Junnikkala S, Paetau A, Kangasniemi M, Peláez J, Hernesniemi J, Niemelä M, Meri S: Complement system becomes activated by the classical pathway in intracranial aneurysm walls. Lab Invest 2010, 90:168-179
11. Cunningham PN, Quigg RJ: Contrasting roles of complement activation and its regulation in membranous nephropathy. J Am Soc Nephrol 2005, 16:1214-1222
12. Theroux P, Martel C: Complement activity and pharmacological inhibition in cardiovascular disease. Can J Cardiol 2006, 22:18B-24B.
13. Okroj M, Heinegard D, Holmdahl R, Blom AM: Rheumatoid arthritis and the complement system. Ann Med 2007, 39:517-530
14. Jamous MA, Nagahiro S, Kitazato KT, Tamura T, Aziz HA, Shono M, Satoh K: Endothelial injury and inflammatory response induced by hemodynamic changes preceding intracranial aneurysm formation: experimental study in rats. J Neurosurg 2007, 107:405-411 (Pubitemid 47219386)
15. Shagdarsuren E, Bidzhekov K, Djalali-Talab Y, Liehn EA, Hristov M, Matthijsen RA, Buurman WA, Zernecke A, Weber C: C1-esterase inhibitor protects against neointima formation after arterial injury in atherosclerosis-prone mice. Circulation 2008, 117:70-78
16. Kassam AB, Horowitz M, Chang YF, Peters D: Altered arterial homeostasis and cerebral aneurysms: a molecular epidemiology study. Neurosurgery 2004, 54:1450-1460
17. Thakkinstian A, Han P, McEvoy M, Smith W, Hoh J, Magnusson K, Zhang K, Attia J: Systematic review and meta-analysis of the association between complement factor H Y402H polymorphisms and age-related macular degeneration. Hum Mol Genet 2006, 15:2784-2790 (Pubitemid 44400405)
18. Happonen KE, Sjoberg AP, Morgelin M, Heinegard D, Blom AM: Complement inhibitor C4b-binding protein interacts directly with small glycoproteins of the extracellular matrix. J Immunol 2009, 182:1518-1525
19. Meri S, Pangburn MK: Discrimination between activators and nonactivators of the alternative pathway of complement: regulation via a sialic acid/polyanion binding site on factor H. Proc Natl Acad Sci USA 1990, 87:3982-3986
20. Oksjoki R, Jarva H, Kovanen PT, Laine P, Meri S, Pentikäinen MO: Association between complement factor H and proteoglycans in early human coronary atherosclerotic lesions: implications for local regulation of complement activation. Arterioscler Thromb Vasc Biol 2003, 23:630-636 (Pubitemid 36438076)
21. Oksjoki R, Kovanen PT, Mäyränpää MI, Laine P, Blom AM, Meri S, Pentikäinen MO: Complement regulation in human atherosclerotic coronary lesions. Immunohistochemical evidence that C4b-binding protein negatively regulates the classical complement pathway, and that C5b-9 is formed via the alternative complement pathway Atherosclerosis 2007, 192:40-48
22. Blom AM, Villoutreix BO, Dahlback B: Complement inhibitor C4b-binding protein-friend or foe in the innate immune system? Mol Immunol 2004, 40:1333-1346
23. Yasojima K, Schwab C, McGeer EG, McGeer PL: Complement components, but not complement inhibitors, are upregulated in atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2001, 21:1214-1219 (Pubitemid 34215153)
24. Michel JB, Thaunat O, Houard X, Meilhac O, Caligiuri G, Nicoletti A: Topological determinants and consequences of adventitial responses to arterial wall injury. Arterioscler Thromb Vasc Biol 2007, 27:1259-1268
25. Ekmekci OB, Ekmekci H: Vitronectin in atherosclerotic disease. Clin Chim Acta 2006, 368:77-83
26. Kim HJ, Yoo EK, Kim JY, Choi YK, Lee HJ, Kim JK, Jeoung NH, Lee KU, Park IS, Min BH, Park KG, Lee CH, Aronow BJ, Sata M, Lee IK: Protective role of clusterin/apolipoprotein J against neointimal hyperplasia via antiproliferative effect on vascular smooth muscle cells and cytoprotective effect on endothelial cells. Arterioscler Thromb Vasc Biol 2009, 29:1558-1564
27. Kardys I, Klaver CC, Despriet DD, Bergen AA, Uitterlinden AG, Hofman A, Oostra BA, Van Duijn CM, de Jong PT, Witteman JC: A common polymorphism in the complement factor H gene is associated with increased risk of myocardial infarction: the Rotterdam Study. J Am Coll Cardiol 2006, 47:1568-1575
28. Zee RY, Diehl KA, Ridker PM: Complement factor H Y402H gene polymorphism. C-reactive protein, and risk of incident myocardial infarction, ischaemic stroke, and venous thromboembolism: a nested case-control study. Atherosclerosis 2006, 187:332-335
29. Nicaud V, Francomme C, Ruidavets JB, Luc G, Arveiler D, Kee F, Evans A, Morrison C, Blankenberg S, Cambien F, Tiret L: Lack of association between complement factor H polymorphisms and coronary artery disease or myocardial infarction. J Mol Med 2007, 85:771-775
30. Stark K, Neureuther K, Sedlacek K, Hengstenberg W, Fischer M, Baessler A, Wiedmann S, Jeron A, Holmer S, Erdmann J, Schunkert H, Hengstenberg C: The common Y402H variant in complement factor H gene is not associated with susceptibility to myocardial infarction and its related risk factors. Clin Sci (Lond) 2007, 113:213-218
31. Laine M, Jarva H, Seitsonen S, Haapasalo K, Lehtinen MJ, Lindeman N, Anderson DH, Johnson PT, Jarvela I, Jokiranta TS, Hageman GS, Immonen I, Meri S: Y402H polymorphism of complement factor H affects binding affinity to C-reactive protein. J Immunol 2007, 178:3831-3836
32. Sjoberg AP, Trouw LA, Clark SJ, Sjolander J, Heinegard D, Sim RB, Day AJ, Blom AM: The factor H variant associated with age-related macular degeneration (His-384) and the non-disease-associated form bind differentially to C-reactive protein, fibromodulin. DNA, and necrotic cells. J Biol Chem 2007, 282:10894-10900
33. Väkevä A, Laurila P, Meri S: Loss of expression of protectin (CD59) is associated with complement membrane attack complex deposition in myocardial infarction. Lab Invest 1992, 67:608-616
34. Inci S, Spetzler RF: Intracranial aneurysms and arterial hypertension: a review and hypothesis. Surg Neurol 2000, 53:530-540 (Pubitemid 30625159)
35. Seifert PS, Roth I, Schmiedt W, Oelert H, Okada N, Okada H, Bhakdi S: CD59 (homologous restriction factor 20), a plasma membrane protein that protects against complement C5b-9 attack, in human atherosclerotic lesions. Atherosclerosis 1992, 96:135-145
36. Wu G, Hu W, Shahsafaei A, Song W, Dobarro M, Sukhova GK, Bronson RR, Shi GP, Rother RP, Halperin JA, Qin X: Complement regulator CD59 protects against atherosclerosis by restricting the formation of complement membrane attack complex. Circ Res 2009, 104:550-558
37. Hallstrom T, Jarva H, Riesbeck K, Blom AM: Interaction with C4b-binding protein contributes to nontypeable Haemophilus influenzae serum resistance. J Immunol 2007, 178:6359-6366
38. Storstein A, Knudsen A, Bjorge L, Meri S, Vedeler C: Heterogeneous expression of CD59 on human Purkinje cells. Neurosci Lett 2004, 362:21-25